EA201791982A1 - Способы лечения неалкогольной жировой болезни печени и/или липодистрофии - Google Patents

Способы лечения неалкогольной жировой болезни печени и/или липодистрофии

Info

Publication number
EA201791982A1
EA201791982A1 EA201791982A EA201791982A EA201791982A1 EA 201791982 A1 EA201791982 A1 EA 201791982A1 EA 201791982 A EA201791982 A EA 201791982A EA 201791982 A EA201791982 A EA 201791982A EA 201791982 A1 EA201791982 A1 EA 201791982A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lipodystrophy
methods
treating
nafld
compositions
Prior art date
Application number
EA201791982A
Other languages
English (en)
Russian (ru)
Inventor
Кристос Мантзорос
Original Assignee
Интекрин Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интекрин Терапьютикс, Инк. filed Critical Интекрин Терапьютикс, Инк.
Publication of EA201791982A1 publication Critical patent/EA201791982A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201791982A 2015-03-09 2016-03-07 Способы лечения неалкогольной жировой болезни печени и/или липодистрофии EA201791982A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562130488P 2015-03-09 2015-03-09
PCT/US2016/021162 WO2016144862A1 (en) 2015-03-09 2016-03-07 Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

Publications (1)

Publication Number Publication Date
EA201791982A1 true EA201791982A1 (ru) 2020-02-17

Family

ID=56879272

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791982A EA201791982A1 (ru) 2015-03-09 2016-03-07 Способы лечения неалкогольной жировой болезни печени и/или липодистрофии

Country Status (16)

Country Link
US (3) US10555929B2 (enExample)
EP (1) EP3267994A4 (enExample)
JP (2) JP2018507914A (enExample)
KR (2) KR20220070057A (enExample)
CN (1) CN107683135A (enExample)
AU (2) AU2016229982B2 (enExample)
BR (1) BR112017019170A2 (enExample)
CA (1) CA2979033A1 (enExample)
EA (1) EA201791982A1 (enExample)
HK (1) HK1249847A1 (enExample)
IL (1) IL254282A0 (enExample)
MA (1) MA42450A (enExample)
MX (2) MX386778B (enExample)
SG (2) SG11201707276PA (enExample)
TW (1) TWI769976B (enExample)
WO (1) WO2016144862A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
SG11201707276PA (en) 2015-03-09 2017-10-30 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CN110382012B (zh) 2016-11-04 2023-08-25 儿童医院医学中心 肝类器官疾病模型以及其制备和使用方法
CN110062764B (zh) 2016-12-05 2024-07-02 儿童医院医学中心 结肠类器官及其制备和使用方法
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
JP7506657B2 (ja) 2018-07-26 2024-06-26 チルドレンズ ホスピタル メディカル センター 肝胆膵組織およびその作製方法
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
GB2577723A (en) 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
JP2022516509A (ja) * 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
EP3946336A1 (en) * 2019-04-02 2022-02-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220193065A1 (en) * 2019-04-04 2022-06-23 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205024A1 (en) * 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205025A1 (en) * 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205023A1 (en) * 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2021076616A1 (en) * 2019-10-15 2021-04-22 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤
CN118406749A (zh) * 2024-02-29 2024-07-30 安徽医科大学 Caveolin-1基因在制备预防、治疗或缓解非酒精性脂肪肝病的药物中的应用

Family Cites Families (402)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE296075C (enExample)
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS61100519A (ja) 1984-10-23 1986-05-19 Shin Etsu Chem Co Ltd 医薬用硬質カプセル
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DD296075A5 (de) 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
EP0528858B1 (en) 1990-04-14 1997-01-22 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ES2153831T3 (es) 1991-10-22 2001-03-16 New England Medical Center Inc Inhibidores de dipeptidil-aminopeptidasa de tipo iv.
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
AU4721897A (en) 1996-10-25 1998-05-22 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
EP1629849B2 (en) 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
BR9813233A (pt) 1997-09-29 2000-08-22 Point Therapeutics Inc Estimulação de células hematopoéticas in vitro
DE69839279T2 (de) 1997-11-18 2009-05-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Neue physiologisch aktive substanz sulphostin, herstellung und verwendung derselben
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1053227B1 (en) 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
EP2433623A1 (en) 1998-02-02 2012-03-28 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US20020061839A1 (en) 1998-03-09 2002-05-23 Scharpe Simon Lodewijk Serine peptidase modulators
TWI252107B (en) 1998-05-04 2006-04-01 Piint Therapeutics Inc Pharmaceutical compositions and kits for hematopoietic usage
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
BR9910907A (pt) 1998-06-05 2002-02-13 Point Therapeutics Inc Compostos cìclicos de boroprolina
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
EP1104293A1 (en) 1998-08-21 2001-06-06 Point Therapeutics, Inc. Regulation of substrate activity
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
ES2302390T3 (es) 1998-12-07 2008-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogos de glp-1.
KR20010093813A (ko) 1998-12-09 2001-10-29 와이즈먼 앤드루 카르바메이트 결합을 포함하는 템플레이트로서 작용하는분자 스캐폴드
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP2000191616A (ja) 1998-12-24 2000-07-11 Senju Pharmaceut Co Ltd 新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬
DE60021166T3 (de) 1999-01-14 2019-08-22 Amylin Pharmaceuticals, Llc Neue exendin agonist formulierungen und deren verabreichung
JP3018186B1 (ja) 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
JP3716901B2 (ja) 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 セルロースエーテルフィルム
JP4121215B2 (ja) 1999-05-17 2008-07-23 財団法人微生物化学研究会 スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
CA2373643A1 (en) 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
DK1192137T3 (da) 1999-06-30 2013-11-11 Amgen Inc Forbindelser til modulering af PPAR-gamma aktivitet
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US20040152745A1 (en) 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
JP2003535034A (ja) 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
JP2003520849A (ja) 2000-01-24 2003-07-08 ノボ ノルディスク アクティーゼルスカブ 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
EP2266665B1 (en) 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
EP1277729A4 (en) 2000-04-28 2005-05-11 Sankyo Co MODULATORS OF PPAR (GAMMA)
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
SK288236B6 (sk) 2000-06-28 2015-01-07 Amgen Inc. Chinolinylfenylsulfónamidová zlúčenina, jej použitie ako liečivo a farmaceutické prípravky obsahujúce túto zlúčeninu
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
MXPA02012272A (es) 2000-07-04 2003-04-25 Novo Nordisk As Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
AU7775401A (en) 2000-08-10 2002-02-25 Welfide Corp Proline derivatives and use thereof as drugs
JP4329291B2 (ja) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 含窒素五員環化合物
JP4329290B2 (ja) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 脂肪族含窒素五員環化合物
JP2004035574A (ja) 2000-10-06 2004-02-05 Tanabe Seiyaku Co Ltd 脂肪族含窒素五員環化合物
ATE407924T1 (de) 2000-10-06 2008-09-15 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
AUPR107800A0 (en) 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002051836A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
DE10100053A1 (de) 2001-01-02 2002-08-22 Keyneurotek Ag I G Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen
AU2002233288B9 (en) 2001-01-02 2007-08-09 Imtm Gmbh Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
WO2002055088A1 (en) 2001-01-16 2002-07-18 Nippon Kayaku Kabushiki Kaisha Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
IL157179A0 (en) 2001-02-02 2004-02-08 Takeda Chemical Industries Ltd Fused heterocyclic compounds
JP4213390B2 (ja) 2001-02-02 2009-01-21 武田薬品工業株式会社 縮合複素環化合物
PT1757606E (pt) 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
JP2002265439A (ja) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
US7026316B2 (en) 2001-03-27 2006-04-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2822826B1 (fr) 2001-03-28 2003-05-09 Servier Lab Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
EP1406872B1 (en) 2001-06-20 2007-12-19 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000181A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
ES2296962T3 (es) 2001-06-27 2008-05-01 Smithkline Beecham Corporation Pirrolidinas como inhibidores de dipeptidil peptidasa.
CA2418543A1 (en) 2001-06-27 2003-01-09 Probiodrug Ag New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
ZA200300833B (en) 2001-06-27 2004-02-10 Probiodrug Ag Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents.
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
JP2005502624A (ja) 2001-07-03 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病を治療するための、ｄｐｐ−ｉｖを阻害するプリン誘導体
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
SG143981A1 (en) 2001-08-31 2008-07-29 Semiconductor Energy Lab Laser irradiation method, laser irradiation apparatus, and method of manufacturing a semiconductor device
DE10143840A1 (de) 2001-09-06 2003-03-27 Probiodrug Ag Neue Inhibitoren der Dipeptidylpeptidase I
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
US20040259883A1 (en) 2001-09-14 2004-12-23 Hiroshi Sakashita Thiazolidine derivative and medicinal use thereof
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
WO2003038123A2 (en) 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
US20030125304A1 (en) 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
US7236683B2 (en) 2001-11-15 2007-06-26 Macrovision Corporation Method and apparatus for providing or enhancing copy protection by adding selected negative-going and positive-going pulses in a video signal HBI
CA2466870A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
EP2316470A3 (en) 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US6725848B2 (en) 2002-01-18 2004-04-27 Detroit Diesel Corporation Method of controlling exhaust gas recirculation system based upon humidity
US20030232788A1 (en) 2002-02-08 2003-12-18 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases
CN1308311C (zh) 2002-02-13 2007-04-04 霍夫曼-拉罗奇有限公司 新型吡啶－和喹啉－衍生物
CA2474578C (en) 2002-02-13 2009-08-25 F. Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
US6906074B2 (en) 2002-02-22 2005-06-14 Nippon Zoki Pharmaceutical Co., Ltd. 2-phenylpiperazine derivatives
DE60304911D1 (de) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthin-Derivate als DPP-IV-Inhibitoren
JP2004043429A (ja) 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
EA007434B1 (ru) 2002-02-28 2006-10-27 Прозидион Лимитед Ингибиторы dpiv на основе глутаминила
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AU2003225916A1 (en) 2002-03-25 2003-10-13 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7348318B2 (en) 2002-03-25 2008-03-25 Nippon Kayaku Kabushiki Kaisha α-Amino-N-(diaminophosphinyl)lactam derivatives
JP4329382B2 (ja) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 医薬組成物
JP4329381B2 (ja) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 医薬組成物
MXPA04009784A (es) 2002-04-08 2004-12-13 Torrent Pharmaceuticlas Ltd Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
US20040106802A1 (en) 2002-04-08 2004-06-03 Torrent Pharmaceuticals Ltd. Novel compounds and therapeutic uses thereof
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
WO2003095425A1 (en) 2002-05-09 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Cyanopyrrolidine derivatives
JP2004026820A (ja) 2002-05-09 2004-01-29 Taisho Pharmaceut Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤
JP2003327532A (ja) 2002-05-10 2003-11-19 Takeda Chem Ind Ltd ペプチダーゼ阻害剤
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
WO2003101448A1 (en) 2002-06-03 2003-12-11 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003101958A2 (en) 2002-06-04 2003-12-11 Pfizer Products Inc. Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
WO2003101449A2 (en) 2002-06-04 2003-12-11 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
TWI273104B (en) 2002-06-06 2007-02-11 Eisai Co Ltd Novel fused imidazole derivative
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
JP2004026678A (ja) 2002-06-24 2004-01-29 Microbial Chem Res Found ２型糖尿病治療剤
IL166157A0 (en) 2002-07-09 2006-01-15 Point Therapeutics Inc Methods and compositions relating to isoleucine boroproline compounds
JPWO2004007446A1 (ja) 2002-07-10 2005-11-10 アステラス製薬株式会社 新規なアゼチジン誘導体又はその塩
ATE451369T1 (de) 2002-07-15 2009-12-15 Merck & Co Inc Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
TW200401635A (en) 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
JP4153911B2 (ja) 2002-07-29 2008-09-24 田辺三菱製薬株式会社 ジペプチジルペプチダーゼｉｖの立体構造
JP4542757B2 (ja) 2002-08-08 2010-09-15 武田薬品工業株式会社 縮合複素環化合物
TW200404060A (en) 2002-08-08 2004-03-16 Takeda Chemical Industries Ltd Fused heterocyclic compounds
DE10238243A1 (de) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BR122012026540B8 (pt) 2002-08-21 2021-05-25 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-il]-xantinas, seus sais farmacêuticamente aceitáveis, seu uso e seu processo de preparação, bem como medicamento e seu processo de preparação
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
JPWO2004019352A1 (ja) 2002-08-26 2005-12-15 松下電器産業株式会社 マルチフェーズ用磁性素子とその製造方法
US7304166B2 (en) 2002-08-29 2007-12-04 Taisho Pharmaceutical Co., Ltd. Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivatives
US8895541B2 (en) 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
AU2003262059A1 (en) 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
US7238724B2 (en) 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20040121964A1 (en) 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2004032836A2 (en) 2002-10-07 2004-04-22 Merck & Co., Inc. Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
WO2004033455A2 (en) 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US7101871B2 (en) 2002-10-18 2006-09-05 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1553937B1 (en) 2002-10-23 2010-06-02 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
WO2004041795A1 (en) 2002-10-30 2004-05-21 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
AU2003280680A1 (en) 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
WO2004043940A1 (en) 2002-11-07 2004-05-27 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2004046106A1 (en) 2002-11-18 2004-06-03 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE10256264A1 (de) 2002-12-03 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7109192B2 (en) 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US7309714B2 (en) 2002-12-04 2007-12-18 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
JP2006512334A (ja) 2002-12-10 2006-04-13 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ
US20060052382A1 (en) 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2512546A1 (en) 2003-01-17 2004-08-05 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004244412A (ja) 2003-01-20 2004-09-02 Kotobuki Seiyaku Kk ４位に置換基を有する２−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤
JP4345313B2 (ja) 2003-01-24 2009-10-14 株式会社日立製作所 ポリシーに基づいたストレージシステムの運用管理方法
WO2004067509A1 (ja) 2003-01-31 2004-08-12 Sanwa Kagaku Kenkyusho Co., Ltd. ジペプチジルペプチダーゼivを阻害する化合物
EP1592689A4 (en) 2003-01-31 2008-12-24 Merck & Co Inc 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2004071454A2 (en) 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004076433A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
AR043515A1 (es) 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc Process to chiral beta-amino acid derivatives
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004087650A2 (en) 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2004092128A1 (en) 2003-04-10 2004-10-28 Smithkline Beecham Corporation Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
JPWO2004096806A1 (ja) 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
US20040229848A1 (en) 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
US20040224995A1 (en) 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
CA2524531A1 (en) 2003-05-14 2004-12-02 Merck And Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JPWO2004101514A1 (ja) 2003-05-15 2006-07-13 大正製薬株式会社 シアノフルオロピロリジン誘導体
EP1631680A2 (en) 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2004104215A2 (en) 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
AU2003902828A0 (en) 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
WO2004110436A1 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
AU2003902946A0 (en) 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
US7456204B2 (en) 2003-06-17 2008-11-25 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
MXPA05013734A (es) 2003-06-20 2006-03-08 Hoffmann La Roche Hexahidropiroisoquinolinas como inhibidores de dpp-iv.
KR100730867B1 (ko) 2003-06-20 2007-06-20 에프. 호프만-라 로슈 아게 Ｄｐｐ-ⅳ 억제제로서의 피리도[2,1-ａ]이소퀴놀린 유도체
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2005023038A (ja) 2003-07-04 2005-01-27 Taisho Pharmaceut Co Ltd 慢性腎疾患治療薬
ATE411980T1 (de) 2003-07-21 2008-11-15 Smithkline Beecham Corp (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon
PE20050249A1 (es) 2003-07-25 2005-06-01 Aventis Pharma Gmbh Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
DE10333935A1 (de) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7259160B2 (en) 2003-07-31 2007-08-21 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20050065183A1 (en) 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
DE10337074A1 (de) 2003-08-12 2005-03-17 Keyneurotek Ag Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
JPWO2005021550A1 (ja) 2003-08-29 2006-10-26 大日本住友製薬株式会社 二環性ピラゾール誘導体
WO2005020920A2 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2005023762A1 (en) 2003-09-04 2005-03-17 Abbott Laboratories Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20070072810A1 (en) 2003-10-03 2007-03-29 Takeda Pharmaceutical Company, Limited Agent for treating diabetes
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
TW200519105A (en) 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
US20070123470A1 (en) 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
KR20100012105A (ko) 2003-10-31 2010-02-05 다케다 야쿠힌 고교 가부시키가이샤 인슐린 감작제, 인슐린 분비촉진제 및 폴리옥시에틸렌 소르비탄 지방산 에스테르를 함유하는 고체 제제
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CN1870990A (zh) 2003-11-04 2006-11-29 默克公司 作为糖尿病治疗或预防用二肽基肽酶iv抑制剂的稠合苯基丙氨酸衍生物
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
HRP20141155T1 (hr) 2003-11-12 2015-01-16 Sino-Med International Alliance, Inc. Heterocikliäśki spojevi borne kiseline
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR20170005163A (ko) 2003-11-17 2017-01-11 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
WO2005051949A1 (ja) 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. 新規縮合イミダゾール誘導体
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2005056541A1 (ja) 2003-12-11 2005-06-23 Mitsubishi Pharma Corporation α-アミノ酸誘導体及びその医薬用途
WO2005058849A1 (en) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
US7217711B2 (en) 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
EP1559419A1 (en) 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
KR20050076924A (ko) 2004-01-26 2005-07-29 삼성전자주식회사 양방향 통신이 가능한 ｉ2ｃ 통신시스템 및 그 방법
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
BRPI0507905A (pt) 2004-02-20 2007-07-10 Novartis Ag uso de compostos orgánicos
US20050203027A1 (en) 2004-02-23 2005-09-15 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV
WO2005082849A1 (en) 2004-02-23 2005-09-09 Trustees Of Tufts College Lactams as conformationally constrained peptidomimetic inhibitors
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US20050215603A1 (en) 2004-03-08 2005-09-29 Irini Akritopoulou-Zanze Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050250820A1 (en) 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
US7348346B2 (en) 2004-03-08 2008-03-25 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
KR100844593B1 (ko) 2004-03-09 2008-07-07 내셔날 헬스 리서치 인스티튜트 피롤리딘 화합물
US20070093492A1 (en) 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7179809B2 (en) 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7671073B2 (en) 2004-05-18 2010-03-02 Merck Sharp & Dohme Corp. Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1753730A1 (en) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP5010918B2 (ja) 2004-07-21 2012-08-29 キッセイ薬品工業株式会社 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
KR100954308B1 (ko) 2004-07-23 2010-04-21 일렉트릭 파워 리서치 인스티튜트, 인크. 플렉시블 전자기 음향 변환기 센서
US7054436B2 (en) 2004-08-02 2006-05-30 Sony Ericsson Mobile Communication, Ab Communication terminals with a dual use speaker for sensing background noise and generating sound, and related methods and computer program products
US20060046978A1 (en) 2004-08-31 2006-03-02 Morphochem Ag Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20060094693A1 (en) 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
WO2006040625A1 (en) 2004-10-12 2006-04-20 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
EP1812378A2 (en) 2004-10-13 2007-08-01 University of Connecticut Cannabinergic lipid ligands
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
BRPI0516667A (pt) 2004-11-30 2008-09-16 Hoffmann La Roche compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização desses compostos
DE602005009745D1 (de) 2004-12-16 2008-10-23 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
KR100904829B1 (ko) 2004-12-20 2009-06-25 에프. 호프만-라 로슈 아게 4-아미노피페리딘 유도체
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MX2007011546A (es) 2005-03-22 2007-10-19 Hoffmann La Roche Nueva sal y polimorfos del inhibidor de dipeptidil-peptidasa iv.
ES2477868T3 (es) 2005-04-22 2014-07-18 Alantos Pharmaceuticals Holding, Inc. Inhibidores de dipeptidil peptidasa-IV
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7644148B2 (en) 2005-05-16 2010-01-05 Hewlett-Packard Development Company, L.P. Historical data based workload allocation
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US20060264433A1 (en) 2005-05-23 2006-11-23 Backes Bradley J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060270722A1 (en) 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
EP1905450A1 (en) 2005-07-12 2008-04-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar gamma agonist
JP2009504599A (ja) 2005-08-11 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー Ｄｐｐ−ｉｖ阻害剤を含有する医薬組成物
US7425633B2 (en) 2005-08-26 2008-09-16 National Health Research Institutes Pyrrolidine compounds
WO2007027651A2 (en) 2005-08-30 2007-03-08 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
DE602006017566D1 (de) 2005-08-30 2010-11-25 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
BRPI0615882A2 (pt) 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AT502717A1 (de) 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
EP1971614A1 (en) 2005-11-14 2008-09-24 Probiodrug AG Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
ES2351471T3 (es) 2005-12-21 2011-02-07 F. Hoffmann-La Roche Ag Nueva sal y polimorfo de inhibidores de dpp-iv.
KR20080080126A (ko) 2005-12-22 2008-09-02 다케다 야쿠힌 고교 가부시키가이샤 인슐린 감작제를 함유하는 고체 제제
WO2007093610A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US20070239536A1 (en) 2006-04-05 2007-10-11 General Electric Company System and method for scheduling audience deficiency units and makegoods
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PT2032134E (pt) * 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
SI2046292T1 (sl) 2006-07-21 2010-06-30 Novartis Ag Formulacije za benzimidazolil piridil etre
WO2008049923A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
CL2007003187A1 (es) 2006-11-06 2008-03-07 Boehringer Ingelheim Int Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
US20100298243A1 (en) 2006-11-09 2010-11-25 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
WO2008067378A2 (en) 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
US20070172525A1 (en) 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
EP2148659A2 (en) 2007-04-13 2010-02-03 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
CA2693628A1 (en) 2007-07-11 2009-01-15 Cardoz Ab New combination for use in the treatment of imflammatory disorders
WO2009015179A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009097996A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
EP2242747A1 (de) 2008-02-07 2010-10-27 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009111078A2 (en) 2008-03-06 2009-09-11 Intekrin Therapeutics, Inc. Combination of a ppary agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity
JPWO2009151116A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US20100087481A1 (en) 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
JP2010265216A (ja) 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物
PL2448412T3 (pl) 2009-07-01 2019-11-29 Jds Therapeutics Llc Kompleksy chromu jako środki podnoszące poziom transporterów glukozy w mózgu
WO2011017488A2 (en) * 2009-08-05 2011-02-10 Intekrin Therapeutics, Inc. Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
US8477001B2 (en) 2010-09-21 2013-07-02 Remy Technologies Llc Starter solenoid with rectangular coil winding
WO2012040082A2 (en) 2010-09-21 2012-03-29 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
WO2012040550A1 (en) 2010-09-26 2012-03-29 Da Yu Enterprises, L.L.C. Method of recombinant macromolecular production
WO2012071459A1 (en) 2010-11-22 2012-05-31 The Regents Of The University Of California New indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease
TWI435605B (zh) 2010-11-29 2014-04-21 Realtek Semiconductor Corp 透過高解析度多媒體介面來進行網路連線之網路裝置及網路連線方法
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
US9044433B2 (en) 2011-10-06 2015-06-02 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
WO2013071077A1 (en) 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
JP5525511B2 (ja) * 2011-12-27 2014-06-18 農業生産法人株式会社 熱帯資源植物研究所 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
KR101186500B1 (ko) 2012-01-31 2012-09-27 연세대학교 산학협력단 신규한 피페린 유도체 및 그의 용도
US9499472B2 (en) 2012-03-05 2016-11-22 The University Of Montana Aspartylamide inhibitors of excitatory amino acid transporters
JP2015533163A (ja) 2012-10-12 2015-11-19 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症における視床損傷を低減するためのラキニモド
EA029216B1 (ru) 2013-01-30 2018-02-28 Интекрин Терапьютикс, Инк. РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP3660512B1 (en) 2013-03-15 2024-07-24 SomaLogic Operating Co., Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
TW201609098A (zh) 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
RU2016138136A (ru) 2014-02-27 2018-04-02 Нусерт Сайенсиз, Инк. Композиции и способы уменьшения или профилактики жировой дистрофии печени
EP3203999B1 (en) 2014-10-10 2020-01-08 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
CN104299589B (zh) 2014-10-29 2016-05-25 京东方科技集团股份有限公司 移位寄存器单元电路、移位寄存器、驱动方法及显示装置
KR20160061492A (ko) 2014-11-21 2016-06-01 삼성디스플레이 주식회사 휴대용 먼지 센서 및 이를 이용한 휴대전화
SG11201707276PA (en) * 2015-03-09 2017-10-30 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CA2981507A1 (en) 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
WO2017139588A1 (en) 2016-02-12 2017-08-17 Indiana University Research & Technology Corporation Lysosomal acid lipase and ppar gamma ligands as an immune therapies for cancer treatment
BR112018075135A2 (pt) 2016-06-08 2019-03-26 Support Venture Gmbh combinações farmacêuticas para tratar câncer
CA3034258A1 (en) 2016-08-18 2018-02-22 Intekrin Therapeutics, Inc. Ppar.gamma. agonist for treatment of blood cancers
SG11201901328VA (en) 2016-08-18 2019-03-28 Intekrin Therapeutics Inc Ppar? agonist for treatment of bone disorders
CN110461318A (zh) 2016-09-13 2019-11-15 因特克林治疗股份有限公司 用chs-131治疗多发性硬化
US11350844B2 (en) 2016-11-23 2022-06-07 Mayo Foundation For Medical Education And Research System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography
RS66854B1 (sr) 2017-01-11 2025-06-30 Kowa Co Pemafibrat u kombinaciji sa inhibitorom sglt2 za profilaktički ili terapeutski tretman bolesti jetre, nealkoholne bolesti masne jetre
WO2018136635A1 (en) 2017-01-18 2018-07-26 Coherus Biosciences, Inc. Pparϒ agonist for the treatment of huntington's disease
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
SG11201909168VA (en) 2017-04-18 2019-11-28 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
EA201992364A1 (ru) 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА
JP2022516509A (ja) 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
EP3946336A1 (en) 2019-04-02 2022-02-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205025A1 (en) 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2021076616A1 (en) 2019-10-15 2021-04-22 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)

Also Published As

Publication number Publication date
AU2016229982B2 (en) 2020-06-18
SG11201707276PA (en) 2017-10-30
JP2021063088A (ja) 2021-04-22
WO2016144862A1 (en) 2016-09-15
US11400072B2 (en) 2022-08-02
US20160263098A1 (en) 2016-09-15
AU2020233626A1 (en) 2020-10-08
US10772865B2 (en) 2020-09-15
HK1249847A1 (zh) 2018-11-16
EP3267994A4 (en) 2018-10-31
EP3267994A1 (en) 2018-01-17
CN107683135A (zh) 2018-02-09
AU2016229982A1 (en) 2017-09-21
SG10202103552XA (en) 2021-05-28
MX386778B (es) 2025-03-19
US10555929B2 (en) 2020-02-11
BR112017019170A2 (pt) 2018-07-10
KR20180006881A (ko) 2018-01-19
TW201639571A (zh) 2016-11-16
KR20220070057A (ko) 2022-05-27
US20200147036A1 (en) 2020-05-14
TWI769976B (zh) 2022-07-11
MA42450A (fr) 2018-05-23
AU2020233626B2 (en) 2022-06-02
MX2021011949A (es) 2021-11-03
US20200383945A1 (en) 2020-12-10
MX2017011586A (es) 2017-10-26
JP2018507914A (ja) 2018-03-22
IL254282A0 (en) 2017-10-31
CA2979033A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
EA201791982A1 (ru) Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
EA201792562A1 (ru) Глюкагон и коагонисты гпп-1
IL264049A (en) Compounds, preparations and methods for treating the disease
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX387817B (es) Uso de acidos grasos de cadena corta en prevencion de cancer.
ITUB20153066A1 (it) Composizione alimentare e/o nutraceutica contenente pea
IL257784A (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
IL263460A (en) Preparations and methods for the treatment of cardiovascular diseases
HK1246800A1 (zh) 用於营养组合物的寡糖组合物和其制造方法
DK3182996T3 (da) Fremgangsmåder til behandling af myelomatose med immunmodulatoriske forbindelser i kombination med antistoffer
DK3357343T3 (da) Fedtsammensætning og fremgangsmåde til fremstilling heraf
HK1245158A1 (zh) 阿吡莫德组合物及其使用方法
LT3496743T (lt) Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais
EP3536159A4 (en) CHOCOLATE COMPOSITION WITH IMPROVED WORKABILITY AND PRODUCTION METHOD THEREFOR
MX2016010447A (es) Composiciones y metodos para tratar diabetes y enfermedades hepáticas.
HK1245586A1 (zh) 使用高脂肪人乳预防和治疗支气管肺发育不良的方法
PL3348273T3 (pl) Kompozycje na bazie ksyloglukanu i białek do leczenia zaburzeń jelitowych
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
EA201691452A1 (ru) Композиции для применения в лечении аллергических состояний
EP3340978A4 (en) COMPOSITIONS AND METHODS FOR TREATING THE RECOGNITION AND TREATMENT OF TUMORS OF THE EWING FAMILY
PL3285791T3 (pl) Kompozycja do leczenia gardła/jamy gardłowej
SG11202003174VA (en) Method and composition for treating hepatocellular carcinoma without viral infection by controlling the lipid homeostasis